Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.
Syndi is a digital health platform that focuses on enhancing health outcomes through technology and research, initially targeting mental health. The platform employs machine learning and digital phenotyping to provide personalized and immediate care by utilizing moment-by-moment passive smartphone data collection. This approach allows for effective and accessible support tailored to individual needs. Syndi's services aim to improve the treatment of invisible disabilities by facilitating connections between patients and healthcare providers, while also measuring the effectiveness of its applications and digital services. Through its innovative solutions, Syndi seeks to transform the way people access and engage with healthcare.
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials.
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling it to provide breakthrough therapeutics to addiction sufferers in desperate need.
PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
CONNECT Care gives patients the confidence to manage their medications.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Paranimo is connecting clients and therapists via its online platform to help overcome challenges in finding the right care locally.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
CONNECT Care gives patients the confidence to manage their medications.
Paranimo is connecting clients and therapists via its online platform to help overcome challenges in finding the right care locally.
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.
Developer of fertility therapy devices designed to provide clinical-standard treatment at home. The company's product contains ovulation assessments, insemination units, pregnant assessments, semen pattern assortment pots, and entry to an application to assist in observing ovulation dates, enabling customers to access affordable fertility treatment in the comfort of their houses.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Camallergy Limited, founded in 2015 and based in Cambridge, United Kingdom, specializes in the development and manufacture of oral immunotherapy drugs targeting food allergies, particularly peanut allergies. The company's innovative treatments aim to provide a patient-centric solution that offers rapid protection, allowing individuals to manage their allergies effectively within a few weeks of therapy. By focusing on the needs of those affected by food allergies, Camallergy seeks to enhance the quality of life for patients, enabling them to live without the constant fear associated with allergic reactions.
Aramune Technologies is developing natural, plant derived feed materials which can be mixed with standard animal feeds to replace antimicrobial agents and promote growth.
4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.
Lumino is focused on enhancing mental health outcomes through the development of digital therapeutic programs. These programs specifically address various mental health concerns and incorporate techniques such as cognitive behavioral therapy (CBT) to help individuals manage their symptoms effectively. Supported by Innovate UK and the Oxford Academic Health Science Network, Lumino aims to leverage digital technology to deliver scalable mental health services, ultimately promoting healthier and happier lives for users.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, established in 2015. The company specializes in developing innovative tissue ablation technology aimed at treating challenging and often inoperable solid cancer tumors. Its proprietary Bimodal Electric Tissue Ablation technology utilizes radiofrequency energy delivered through a specialized probe to create localized heating that destroys targeted tissues. This approach provides healthcare professionals with advanced clinical options for treating cancer, ultimately improving patient outcomes.
DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.
Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.
Directed Systems develops and markets clinical decision support and control systems specifically tailored for anaesthesia, intensive care, and burns centres. The company focuses on creating medical software that facilitates data-driven clinical decisions through clinical optimization applications designed for time-critical conditions. These applications operate using real-time patient monitoring data and include FDA-cleared solutions for cardiovascular management in operating rooms. Directed Systems is also expanding its platform to cover recovery and intensive care settings. By accumulating a vast dataset, the company leverages analytics and AI tools to enhance performance, enabling healthcare professionals to make informed decisions that improve patient outcomes and minimize complications.
Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of a silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have sustained injuries due to trauma or cancer surgery. This innovative approach eliminates the risks associated with traditional autograft procedures, which are currently considered the gold standard for such repairs. By providing healthcare professionals with a new treatment option, Newrotex aims to enhance patient outcomes and reduce the morbidity associated with conventional nerve repair methods. The intellectual property for this device has been granted, underscoring its potential impact in the medical field.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of a silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have sustained injuries due to trauma or cancer surgery. This innovative approach eliminates the risks associated with traditional autograft procedures, which are currently considered the gold standard for such repairs. By providing healthcare professionals with a new treatment option, Newrotex aims to enhance patient outcomes and reduce the morbidity associated with conventional nerve repair methods. The intellectual property for this device has been granted, underscoring its potential impact in the medical field.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Lunac Therapeutics
Grant in 2019
Lunac Therapeutics is a UK-based drug discovery company.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
Healum is a developer of connected software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company's AI-powered platform offers personalized care and support by leveraging data-driven insights and evidence-based behavioral interventions. This approach not only helps patients monitor their physical and mental health effectively but also empowers healthcare professionals to provide tailored assistance. By focusing on customized interventions, Healum seeks to motivate patients in managing their chronic health issues more efficiently and cost-effectively.
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.
MediSieve Ltd. is a London-based medical device company that specializes in developing Magnetic Blood Filtration (MBF) technology for the treatment of blood-borne diseases. The company’s innovative device employs a magnetic filter to remove infected blood cells, making it applicable for conditions such as malaria, leukemia, and sepsis. MediSieve’s system operates by circulating a patient’s blood through an external loop, where targeted magnetic particles bind to specific disease-related targets. The blood is then filtered through a magnetic device that captures these particles and their attached targets, allowing the remainder of the blood to return to the patient without contamination. Founded in 2014 and located at the Imperial Incubator in White City, London, MediSieve has dedicated facilities for product development and validation, including capabilities for various blood testing methods.
PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.
Orbit Discovery Ltd. is a peptide display technology company based in Oxford, United Kingdom, founded in 2015. The company specializes in identifying peptide drugs aimed at treating chronic diseases by leveraging its innovative in vitro display technology. This technology utilizes small beads to connect randomized peptide sequences with their corresponding DNA, facilitating the screening of peptides for various disease types. Orbit Discovery focuses on developing a screening platform that identifies potential peptide drug candidates for both internal drug discovery programs and collaborative research initiatives. The company’s platform offers a means to discover and optimize novel, biologically relevant peptides, capitalizing on the unique properties of peptides that combine the specificity and efficacy of larger biologic molecules with the advantages of smaller molecules, such as reduced dosing and simpler manufacturing processes. This approach aims to enhance the discovery and development of peptide-based therapeutics.
Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
RoslinCT is a prominent UK-based contract development and manufacturing organization specializing in cell therapy. The company offers a range of services tailored for organizations developing cell-based therapeutic products, including cell and gene therapy development, tissue procurement, and cryopreservation studies. Additionally, RoslinCT conducts pre-clinical studies and analytical development, ensuring that clients can deliver compliant, sustainable, and affordable therapies. Through its expertise, RoslinCT supports the advancement of innovative treatments in the field of regenerative medicine.
Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton in collaboration with the University of Warwick, Medherant aims to address the limitations of existing patch technologies, which often struggle with drug loading capabilities and are unsuitable for many pharmaceutical products. The company's flagship product, the TEPI Patch, utilizes a novel adhesive that enhances drug delivery by allowing for higher concentrations and faster release rates, while mitigating the issues associated with oral medications, such as gastrointestinal toxicity and low bioavailability.
Ieso Digital Health Ltd. specializes in providing online evidence-based cognitive behavioral therapy (CBT) to individuals facing various mental health challenges, including anxiety and depression. The company's unique online service facilitates real-time communication between accredited therapists and patients through a secure virtual environment, where sessions are conducted via text. This approach not only mirrors traditional face-to-face interactions but also offers greater convenience for users. Ieso began its operations in the UK in 2000 and has since expanded into the US market, collaborating with Medicaid and commercial health plans to enhance access to mental health services. The company’s therapy model has demonstrated effectiveness, requiring fewer sessions to achieve recovery and showing improved outcomes compared to conventional therapy methods. Ieso serves a diverse clientele, including health providers, private individuals, and businesses, and is recognized for its rapid growth in the digital health sector.
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company’s lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston, US. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, specializing in the development and supply of high-quality reagents, kits, and drug discovery services. Founded in 2009, Ubiquigent focuses on protein degradation, particularly through the innovation of deubiquitylase (DUB) enzyme inhibitors. The company caters to the life science research community by providing drug discovery assay development and compound profiling services, targeting the ubiquitin and ubiquitin-like signaling systems. Ubiquigent collaborates with academic researchers and pharmaceutical scientists to advance drug discovery related to DUB modulators, which hold promise for addressing significant therapeutic needs. Additionally, the company is building a strong intellectual property portfolio that includes inhibitors and compounds aimed at enhancing drug development initiatives.
Almac Group is a prominent contract development and manufacturing organization based in Craigavon, United Kingdom, specializing in a comprehensive array of services for the pharmaceutical and biotech sectors. With over 40 years of organic growth, the company employs more than 4,500 skilled professionals and operates facilities in the UK, Ireland, the United States, and Asia. Almac Group's offerings encompass research and development, biomarker discovery and development, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply, and companion diagnostic development. The group also includes Almac Diagnostics, which focuses on biomarker discovery and validation, providing services such as bioinformatics solutions and genomic analyses. Additionally, Almac Discovery is dedicated to oncology, concentrating on innovative cancer treatment approaches during the discovery and preclinical stages. Through continuous investment in state-of-the-art technology and services, Almac Group supports clients throughout the entire biopharmaceutical product lifecycle, from preclinical development to commercialization.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Phico Therapeutics Limited operates as a biotechnology company that primarily focuses on developing antibiotics to overcome antibacterial resistance. Its SASPject platform delivers anti-bacterial proteins, such as small acid-soluble spore proteins to selected bacterial species using targetable non-delivery vehicles. The company’s portfolio includes SASPject PT3, an antibiotic against Pseudomonas aeruginosa; SASPject PT4 and SASPject PT5 for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2 that targets Staphylococcus aureus. Phico Therapeutics Limited was incorporated in 2000 and is based in Bourn, United Kingdom.
Udamo is a digital therapeutics company focusing on the automation of Cognitive Behavioural Therapy (CBT) interventions.
Bioinduction is a developer of neuromodulation devices aimed at treating chronic pain and various neurological disorders. The company specializes in a deep brain stimulation platform that is both faster and simpler than traditional methods. Its innovative products include a skull-mounted deep brain stimulator, which features advanced capabilities such as neural recording and target steering. This design enhances the productivity of surgical teams and improves patient comfort by utilizing a unique skull location, differentiating Bioinduction’s offerings from conventional deep brain stimulation devices.
Lightpoint Medical, Ltd., a medical device company, develops imaging technologies for cancer surgery. It develops Cerenkov Luminescence Imaging technology that detects cancer in real-time during surgery, and reduces the likelihood of cancer recurrence and the need for reoperation. Lightpoint Medical, Ltd. was formerly known as Artemis Diagnostics Ltd. and changed its name to Lightpoint Medical, Ltd. in January 2013. The company was founded in 2012 and is based in Rickmansworth, United Kingdom.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Emergex Vaccines Holding Ltd is a biotechnology company engaged in the research and development of vaccines for viral and bacterial infectious diseases. Founded in 2016 and based in Abingdon, United Kingdom, Emergex focuses on creating affordable and effective vaccines tailored for low-resource environments that are significantly impacted by pandemics. The company’s vaccine technology targets diseases such as dengue, influenza, zika, hepatitis B, and francisella tularensis. Emergex aims to establish a clinical-grade international vaccine repository that will serve as a first line of defense against both existing and newly emerging infectious disease outbreaks.
Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
PulmonIR is focused on the research and development of innovative medical devices aimed at detecting and monitoring lung diseases, particularly chronic obstructive pulmonary disease (COPD) and lung cancer. The company's technology is designed to assist healthcare professionals in diagnosing COPD patients more efficiently, allowing for quicker and safer treatment options for those suffering from these conditions. By streamlining the testing process, PulmonIR aims to improve patient outcomes and enhance the overall management of lung diseases.
AccuRx Limited is a London-based company established in 2016 that specializes in developing text messaging software for healthcare professionals. Its platform facilitates communication between General Practitioner (GP) practices and patients, offering features such as appointment booking, patient questionnaires, online consultations, and video consultations. The Chain messaging feature allows medical practitioners to send advice, notify patients of test results, and remind them to schedule appointments. Since its inception, AccuRx has expanded its reach significantly, now serving 20% of GP practices in England. The company aims to enhance the connection between patients and their healthcare teams, improving overall communication and patient engagement.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Cobra Biologics Limited specializes in contract manufacturing services for biologics and pharmaceuticals, catering to pre-clinical, clinical, and commercial supply needs. The company offers a comprehensive range of services, including cell line development, GMP cell banking, stability testing, protein characterization, and various analytical services. It focuses on producing mammalian and microbial proteins, along with cGMP virus services essential for gene therapy and vaccine production. Cobra Biologics also provides plasmid DNA services, encompassing both non-GMP and GMP processes, and has expertise in aseptic pharmaceutical manufacturing, freeze-drying, and injectable product filling. With facilities in Keele, United Kingdom, and Södertälje, Sweden, the company has built a strong reputation in the global life sciences sector, supporting the development and commercialization of drugs through a combination of integrated and stand-alone services. Founded in 1992 and formerly known as RecipharmCobra Biologics Limited, Cobra Biologics operates as a subsidiary of Cognate BioServices, Inc.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Spoonful of sugar Ltd. provides evidence-based adherence solutions to healthcare providers. Spoonful of Sugar (SoS) are medicines-related behaviour consultants and solution providers. SoS delivers intelligent medicines engagement programmes and evidence-based adherence solutions on behalf of the pharmaceutical industry and healthcare providers. Our programmes are designed to optimise access and adherence to medication as well as increasing stakeholder concordance and improving health outcomes.
Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.
MIOTIFY Ltd. develops software and online toolkit to boost the quality of digital health applications. The company's system allows both developers and non-IT staff to create applications within a guided framework to help them build in quality from the start and auto-generate evidence to include in a submission for regulatory approval. MIOTIFY Ltd. provides new data to enable medics to monitor patients remotely and gather insights to inform their treatment. MIOTIFY Ltd. was incorporated in 2015 and is based in Windsor, United Kingdom.
Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, focused on DNA therapies and technology. Founded in 2008, the company has developed the proTL synthetic DNA platform, which enables the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach serves various applications including veterinary vaccines, monoclonal antibodies, gene therapy, allergy treatment, RNA interference therapies, and stem cell reprogramming. Touchlight has assembled a skilled team of scientists and drug development experts, led by founder and CEO Jonny Ohlson, who is supported by a dynamic management team. The company has formed strategic collaborations with prestigious academic institutions such as Imperial College London and the University of Pennsylvania, contributing to the advancement of its technologies and the establishment of therapeutic proof-of-principle.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.